| dbo:abstract
|
- Trestolone, also known as 7α-methyl-19-nortestosterone (MENT), is an experimental androgen/anabolic steroid (AAS) and progestogen medication which has been under development for potential use as a form of hormonal birth control for men and in androgen replacement therapy for low testosterone levels in men but has never been marketed for medical use. It is given as an implant that is placed into fat. As trestolone acetate, an androgen ester and prodrug of trestolone, the medication can also be given by injection into muscle. Side effects of trestolone include low estrogen levels and associated symptoms such as reduced sexual function and decreased bone mineral density among others. Trestolone is an AAS, and hence is an agonist of the androgen receptor, the biological target of androgens like testosterone. It is also a progestin, or a synthetic progestogen, and hence is an agonist of the progesterone receptor, the biological target of progestogens like progesterone. Due to its androgenic and progestogenic activity, trestolone has antigonadotropic effects. These effects result in reversible suppression of sperm production and are responsible for the contraceptive effects of trestolone in men. Trestolone was first described in 1963. Subsequently, it was not studied again until 1990. Development of trestolone for potential clinical use started by 1993 and continued thereafter. No additional development appears to have been conducted since 2013. The medication was developed by the Population Council, a non-profit, non-governmental organization dedicated to reproductive health. (en)
|
